{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:02:48Z","timestamp":1791932568220,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research to Prevent Blindness Grant"},{"name":"The Indiana University Medical Student Program for Research"},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K08HD109636"],"award-info":[{"award-number":["K08HD109636"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000912","name":"March of Dimes Foundation","doi-asserted-by":"publisher","award":["Basil O\u2019Connor Award"],"award-info":[{"award-number":["Basil O\u2019Connor Award"]}],"id":[{"id":"10.13039\/100000912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Retinopathy of prematurity (ROP) is a disease that affects preterm infants born younger than 30 weeks of gestation. The pathophysiology of ROP involves an initial vaso-obliterative phase followed by vaso-proliferative phase that leads to disease progression. The use of supplemental oxygen during the vaso-proliferative phase of ROP has been associated with reduced disease progression, but how this impacts the need for ROP treatment is unclear. The goal of this study was to compare the rate of laser or intravitreal bevacizumab after implementation of a new supplemental oxygen therapy protocol in preterm infants with stage 2 ROP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective chart review of preterm infants diagnosed with stage 2 ROP at Riley Hospital for Children between 1\/2017 and 12\/2022. Patients diagnosed between 1\/2017 and 6\/2020 were classified as Cohort A, preprotocol implementation. Patients diagnosed from 8\/2020 to 12\/2022 were classified as Cohort B, postprotocol implementation. In Cohort A, oxygen saturation was kept at 91-95% through the entire hospitalization. In Cohort B, oxygen saturation was increased to 97\u201399% as soon as Stage 2 ROP was diagnosed.\u00a0Statistical analyses were performed using chi-square and Student\u2019s T test, followed by multivariate analyses to determine the impact of the oxygen protocol on the need for ROP treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 211 patients were diagnosed with stage 2 ROP between 1\/2017 and 12\/2022. Of those patients, 122 were before protocol implementation therapy (Cohort A), and 89 were after implementation of supplemental oxygen protocol (Cohort B). Gestational age was slightly higher in Cohort B (Cohort A 25.3\u2009\u00b1\u20091.9, Cohort B 25.8\u2009\u00b1\u20091.84, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). There was no difference in birth weight, NEC, BPD, or survival. Cohort B had lesser need for invasive mechanical ventilation and higher days on CPAP during hospitalization. Notably, Cohort A had 67 (55%) patients treated with laser photocoagulation or intravitreal bevacizumab versus 20 (22%) patients in Cohort B (OR 0.19, 0.08\u20130.40).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The need for laser photocoagulation or intravitreal bevacizumab was significantly decreased in high-risk patients treated with the supplemental oxygen protocol. This result supports the idea that targeted supplemental oxygen therapy to keep saturations between 97 and 99% can reduce disease progression in infants with stage 2 ROP and potentially decrease the burden of additional procedures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-024-03483-w","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T20:20:54Z","timestamp":1716582054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity"],"prefix":"10.1186","volume":"24","author":[{"given":"Robert","family":"Minturn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hartigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanthi","family":"Vegunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Boente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Golzarri-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elleen","family":"Laughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok Lim","family":"Kua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ophtha.2023.04.004","volume":"130","author":"HW Lim","year":"2023","unstructured":"Lim HW, Pershing S, Moshfeghi DM, Heo H, Haque ME, Lambert SR, Consortium IRAC. Causes of Childhood blindness in the United States using the IRIS(R) Registry (Intelligent Research in Sight). Ophthalmology. 2023;130:907\u201313. https:\/\/doi.org\/10.1016\/j.ophtha.2023.04.004","journal-title":"Ophthalmology"},{"key":"3483_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa0911781","volume":"362","author":"SS Network","year":"2010","unstructured":"Network SS, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362:1959\u201369. https:\/\/doi.org\/10.1056\/NEJMoa0911781","journal-title":"N Engl J Med"},{"key":"3483_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/sjopt.sjopt_18_22","volume":"36","author":"YNJ Strube","year":"2022","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022;36:239\u201342. https:\/\/doi.org\/10.4103\/sjopt.sjopt_18_22","journal-title":"Saudi J Ophthalmol"},{"key":"3483_CR4","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1172\/JCI42142","volume":"120","author":"P Sapieha","year":"2010","unstructured":"Sapieha P, Joyal JS, Rivera JC, Kermorvant-Duchemin E, Sennlaub F, Hardy P, Lachapelle P, Chemtob S. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010;120:3022\u201332. https:\/\/doi.org\/10.1172\/JCI42142","journal-title":"J Clin Invest"},{"key":"3483_CR5","first-page":"55","volume":"30","author":"A Molinari","year":"2017","unstructured":"Molinari A, Weaver D, Jalali S. Classifying retinopathy of prematurity. Community Eye Health. 2017;30:55\u20136.","journal-title":"Community Eye Health"},{"key":"3483_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0161-6420(01)00540-1","volume":"108","author":"WV Good","year":"2001","unstructured":"Good WV, Hardy RJ. The multicenter study of early treatment for retinopathy of Prematurity (ETROP). Ophthalmology. 2001;108:1013\u20134. https:\/\/doi.org\/10.1016\/s0161-6420(01)00540-1","journal-title":"Ophthalmology"},{"key":"3483_CR7","doi-asserted-by":"publisher","first-page":"1055813","DOI":"10.3389\/fped.2023.1055813","volume":"11","author":"S Diggikar","year":"2023","unstructured":"Diggikar S, Gurumoorthy P, Trif P, Mudura D, Nagesh NK, Galis R, Vinekar A, Kramer BW. Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: a systematic review and meta-analysis. Front Pediatr. 2023;11:1055813. https:\/\/doi.org\/10.3389\/fped.2023.1055813","journal-title":"Front Pediatr"},{"key":"3483_CR8","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1111\/aos.12053","volume":"91","author":"CS Yang","year":"2013","unstructured":"Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol. 2013;91:e276\u2013282. https:\/\/doi.org\/10.1111\/aos.12053","journal-title":"Acta Ophthalmol"},{"key":"3483_CR9","doi-asserted-by":"publisher","unstructured":"Lee CC, Chiang MC, Chu SM, Wu WC, Ho MM, Lien R. Clinical risk factors for retinopathy of Prematurity Reactivation after Intravitreal Anti-vascular endothelial growth factor injection. J Pediatr. 2024;113913. https:\/\/doi.org\/10.1016\/j.jpeds.2024.113913","DOI":"10.1016\/j.jpeds.2024.113913"},{"key":"3483_CR10","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1007\/s00417-022-05730-6","volume":"260","author":"YB Chou","year":"2022","unstructured":"Chou YB, Wang AG, Yang HY, Chen KJ, Yang CS. Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study. Graefes Arch Clin Exp Ophthalmol. 2022;260:3809\u201316. https:\/\/doi.org\/10.1007\/s00417-022-05730-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3483_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1159\/000531541","volume":"120","author":"AA Baiad","year":"2023","unstructured":"Baiad AA, Kherani IZ, Popovic MM, Katsnelson G, Muni RH, Mireskandari K, Tehrani NN, Zhou TE, Kertes PJ. A Meta-analysis of neurodevelopmental outcomes following Intravitreal Bevacizumab for the treatment of retinopathy of Prematurity. Neonatology. 2023;120:577\u201388. https:\/\/doi.org\/10.1159\/000531541","journal-title":"Neonatology"},{"key":"3483_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/jamaophthalmol.2018.7021","volume":"137","author":"A Shukla","year":"2019","unstructured":"Shukla A, Sonnie C, Worley S, Sharma A, Howard D, Moore J, Rodriguez RJ, Hoppe G, Sears JE. Comparison of biphasic vs static oxygen saturation targets among infants with retinopathy of Prematurity. JAMA Ophthalmol. 2019;137:417\u201323. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.7021","journal-title":"JAMA Ophthalmol"},{"key":"3483_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ophtha.2008.09.051","volume":"116","author":"JE Sears","year":"2009","unstructured":"Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116:513\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2008.09.051","journal-title":"Ophthalmology"},{"key":"3483_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMoa1302298","volume":"368","author":"BIUKC Group","year":"2013","unstructured":"Group BIUKC, Group BIAC, Group BINZC, Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszczak E, Askie L, Battin M, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med. 2013;368:2094\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1302298","journal-title":"N Engl J Med"},{"key":"3483_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1542\/peds.105.2.295","volume":"105","author":"Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of","year":"2000","unstructured":"Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of. Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295\u2013310. https:\/\/doi.org\/10.1542\/peds.105.2.295","journal-title":"Pediatrics"},{"key":"3483_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1167\/iovs.16-20822","volume":"58","author":"TT Colaizy","year":"2017","unstructured":"Colaizy TT, Longmuir S, Gertsch K, Abramoff MD, Klein JM. Use of a Supplemental Oxygen Protocol to suppress progression of retinopathy of Prematurity. Invest Ophthalmol Vis Sci. 2017;58:887\u201391. https:\/\/doi.org\/10.1167\/iovs.16-20822","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3483_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/pr.2016.98","volume":"80","author":"R Cayabyab","year":"2016","unstructured":"Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen saturation targets and retinopathy of prematurity in extremely preterm infants. Pediatr Res. 2016;80:401\u20136. https:\/\/doi.org\/10.1038\/pr.2016.98","journal-title":"Pediatr Res"},{"key":"3483_CR18","doi-asserted-by":"publisher","unstructured":"Good WV. and Early Treatment for Retinopathy of Prematurity Cooperative, G. (2006). The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol 90, 1378\u20131382. https:\/\/doi.org\/10.1136\/bjo.2006.098582","DOI":"10.1136\/bjo.2006.098582"},{"key":"3483_CR19","unstructured":"Team RC. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2023."},{"key":"3483_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jama.2021.23580","volume":"327","author":"EF Bell","year":"2022","unstructured":"Bell EF, Hintz SR, Hansen NI, Bann CM, Wyckoff MH, DeMauro SB, Walsh MC, Vohr BR, Stoll BJ, Carlo WA, et al. Mortality, In-Hospital morbidity, Care practices, and 2-Year outcomes for extremely Preterm infants in the US, 2013\u20132018. JAMA. 2022;327:248\u201363. https:\/\/doi.org\/10.1001\/jama.2021.23580","journal-title":"JAMA"},{"key":"3483_CR21","doi-asserted-by":"publisher","unstructured":"Fang JL, Sorita A, Carey WA, Colby CE, Murad MH, Alahdab F. Interventions to prevent retinopathy of Prematurity: a Meta-analysis. Pediatrics. 2016;137. https:\/\/doi.org\/10.1542\/peds.2015-3387","DOI":"10.1542\/peds.2015-3387"},{"key":"3483_CR22","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1542\/peds.2009-2218","volume":"125","author":"ML Chen","year":"2010","unstructured":"Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125:e1483\u20131492. https:\/\/doi.org\/10.1542\/peds.2009-2218","journal-title":"Pediatrics"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03483-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T20:24:55Z","timestamp":1716582295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03483-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03483-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective review was reviewed and considered as an exempt study by the Institutional Review Board (IRB) of Indiana University School of Medicine. Given that this is an exempted study that analyzed deidentified clinical data, informed consent to participate was waived. This study adhered to the tenants of the Declaration of Helsinki","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Robert Minturn: none.Kelly Hartigan: none.Charline Boente: None.Lilian Golzarri-Arroyo: None.Elizabeth Hynes: none.Elleen Laughlin: none.Sravanthi Vegunta: None.Kathryn Haider: None.Kok Lim Kua: none.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Commercial disclosures"}}],"article-number":"220"}}